Literature DB >> 30324693

Clinicopathological features of hydrophilic polymer emboli in Japanese autopsy cases.

Masashi Miyaoka1, Kazuhito Hatanaka1, Toshimasa Uekusa2, Naoya Nakamura1.   

Abstract

Hydrophilic polymer is used on multiple endovascular devices to decrease friction between these devices and vessel walls. Although it can prevent medical device-related complications, hydrophilic polymer emboli (HPE) has recently been established as a potentially fatal iatrogenic phenomenon. HPE can cause tissue injury in numerous sites, including the brain, heart, lung, skin, and intestines. Most HPE reports have been from Europe and the USA. Therefore, we investigated the frequency, site distribution, and degree of tissue injury of HPE in 227 Japanese autopsy cases. HPE was noted in 3.1% (7/227 cases), and was only found in the lung or heart. There were no cases with tissue injury, such as vasculopathy, ischemia or infarction, associated with HPE. This is the first series study of HPE in Japanese autopsy cases. Unlike in reports from Europe and USA, HPE was only seen in the lung or heart and did not injure the surrounding tissue.
© 2018 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Hydrophilic polymer emboli; autopsy; catheterization; tissue injury

Mesh:

Substances:

Year:  2018        PMID: 30324693     DOI: 10.1111/apm.12891

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  2 in total

1.  Late-onset Cutaneous Hydrophilic Polymer Embolism: A Case Occurring Two Years after Endovascular Procedures.

Authors:  Yukino Kase; Ryota Hayashi; Izumi Takei; Osamu Ansai; Takeo Suzuki; Akihiko Yuki; Mitsuhiro Watanabe; Takao Yanagawa; Riichiro Abe
Journal:  Acta Derm Venereol       Date:  2021-07-30       Impact factor: 3.875

2.  Polymer Emboli Complicating Transcatheter Aortic Valve Implantation: A Case Report.

Authors:  Husam A Noor; Ahmed S Hossain; Rajesh Jayakumar; Abdulla Darwish; Sadananda Shivappa; Haitham Amin; Nooraldaem Yousif
Journal:  JACC Case Rep       Date:  2022-05-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.